课题基金 / 基金详情

THE PURPOSE OF THE TO REQUIREMENT IS TO CONDUCT A PHASE I STUDY OF CBD-MORPHINE DRUG-DRUG INTERACTION. TRI HAS CLEARLY DEFINED THE OBJECTIVES OF THE TO IN THEIR PROPOSAL SUBMISSION.

THE PURPOSE OF THE TO REQUIREMENT IS TO CONDUCT A PHASE I STUDY OF CBD-MORPHINE DRUG-DRUG INTERACTION. TRI HAS CLEARLY DEFINED THE OBJECTIVES OF THE TO IN THEIR PROPOSAL SUBMISSION.
该要求的目的是进行 CBD-吗啡药物相互作用的第一阶段研究。
批准号：
10044332
负责人：
DANIEL MOLINA
金额：
$17.99万
依托单位：
TECHNICAL RESOURCES INTERNATIONAL, INC.
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
项目状态：
已结题
起止时间：
2019-09-20 至 2024-09-19
来源：
https://reporter.nih.gov/project-details/10044332
关键词：
CannabidiolClinicalClinical ResearchClinical Research AssociateDrug InteractionsDrug KineticsMorphinePharmaceutical PreparationsSafetyServicesmorphine-3-glucuronidemorphine-6-glucuronidephase 1 study

项目摘要

项目成果

DANIEL MOLINA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objective of this Task Order is to provide support services for the conduct of a clinical study to determine the effect of CBD on the pharmacokinetics of morphine and 2 of its metabolites (morphine-3-glucuronide and morphine-6-glucuronide). In addition, the safety of the combination will be assessed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE I COCAINE DRUG INTERACTION STUDY. TO6. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 08/10/2023 - 02/09/2025. NIDA REF. NO. N01DA-19-8947.
FY23. TO5. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 01/18/2022 - 04/16/2024. NIDA REF. NO. N01DA-19-8947.
NIAID CLINICAL DATA AND SAFETY MANAGEMENT CENTER (CDSMC)
DATA COORDINATING CENTER FOR SPROUTS AGES 6- AND 7- YEARS ASSESSMENTS AND STUDY CLOSEOUT
国内基金
海外基金
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data